Genoptix

NeoGenomics will pay $125 million in cash and distribute 1 million shares of its stock to Genoptix, a clinical oncology lab, as part of the deal.

The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.

The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.

Upon completion of the transaction, Rosetta will become a privately held subsidiary of Genoptix and its shares will cease to trade on the Nasdaq.

The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.

Genoptix's $9 million bid for Rosetta comes just days after the companies' first merger agreement failed to secure shareholder approval.

Genoptix terminated the merger agreement after an insufficient number of Rosetta shareholders voted in favor of the deal.

Genoptix has also agreed to provide a $1.8 million secured bridge loan facility to fund Rosetta’s operations through the closing of the deal.

The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.

Pages

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.